Adhesive bandages for sties or chalazia

Abstract

Provided herein are small hydrocolloid adhesive bandages for a variety of uses for a subject in need thereof. In some embodiments, the hydrocolloid adhesive bandages disclosed herein are useful for the treatment of sties or chalazia.

Description

ADHESIVE BANDAGES FOR STIES OR CHALAZIACROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 678,796, filed on August 2, 2024, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] A variety of conditions can lead to significant morbidity of the eyelids, including, for example, sties or chalazia, often resulting from blockage or infection of naturally occurring glands in the eyelids. These blockages can trigger immediate inflammatory responses, including eyelid swelling, redness, and pain. Typical treatments have included applying warm compresses, and topical application of antibiotic or steroid creams. However, the effectiveness of these methods is limited and there is an unmet need for improved methods that could speed up symptom resolution and enhance recovery from these eyelid conditions.SUMMARY

[0003] Provided herein is a bandage configured to contour to an eye and append to skin of the palpebra of a subject, wherein the bandage comprises: an inner layer, in contact with the skin of the palpebra, having a first surface that is adhesive to the skin of the palpebra and a second surface that is adhesive to an outer layer, wherein one or more therapeutic agents are disposed on or within the first surface of the inner layer; and the outer layer attached to the second surface of the inner layer and configured to resist permeation of water.

[0004] In some embodiments, a surface area of the bandage is about 30 mm2to about 200 mm2. In some embodiments, a surface area of the bandage is about 40 mm2to about 80 mm2. In some embodiments, a surface area of the bandage is about 50 mm2 to about 70 mm2.

[0005] In some embodiments, the one or more therapeutic agents is effective for treating stye and / or chalazion. In some embodiments, the bandage is configured to cover the skin of the palpebra without interfering with the subject’s vision or function of an eyelid. In some embodiments, the bandage is configured to cover an area affected by stye or chalazion without interfering with the subject’s vision or function of an eyelid.

[0006] In some embodiments, the inner layer is centrally adhesively attached to the outer layer. In some embodiments, the outer layer extends over and covers the inner layer. In some embodiments, the outer layer is the same size as the inner layer.

[0007] In some embodiments, the outer layer has a third surface that is adhesive to the second surface of the inner layer and a fourth surface that faces opposite to the skin. In someembodiments, the third surface of the outer layer is configured to be adhesive to skin around the palpebra without interfering with the subject’s vision or function of an eyelid.

[0008] In some embodiments, a bio-adhesive agent is disposed on a peripheral area of the third surface of the outer layer. In some embodiments, a bio-adhesive agent is disposed on the first surface of the inner layer. In some embodiments, the outer layer is configured to blend into the skin or to be invisible.

[0009] In some embodiments, the inner layer has a circular, semi-circular, or any geometric shape to fit over the area affected by stye or chalazion. In some embodiments, the inner layer is circular and has a diameter of about 5 mm to about 15 mm.

[0010] In some embodiments, the inner layer is flexible and molded to the area affected by stye or chalazion. In some embodiments, the outer layer is flexible and contour to the eye. In some embodiments, the bandage comprises one layer combining the inner layer and the outer layer. In some embodiments, the bandage further comprises one or more additional layers.

[0011] In some embodiments, the bandage comprises a hydrocolloid patch. In some embodiments, the hydrocolloid patch comprises an oval, crescent, circular, semi-circular, or geometric shape to fit contour of the eyelid and to fit over the area affected by stye or chalazion. In some embodiments, the hydrocolloid patch has a circular shape with a diameter of about 0.1 inches to about 0.6 inches. In some embodiments, the hydrocolloid patch has semi-circular shape with a radius of 0.205 inches.

[0012] In some embodiments, the one or more therapeutic agents increase blood circulation of the area affected by stye or chalazion. In some embodiments, the one or more therapeutic agents reduce pain or inflammation of the area affected by stye or chalazion. In some embodiments, the one or more therapeutic agents are selected from the group consisting of steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof. In some embodiments, the one or more therapeutic agents do not cause irritation to the eye or make the subject's vision blurry.

[0013] In some embodiments, the bio-adhesive agent is selected from the group consisting of methacrylate, epoxy diacrylate (vinyl resin), hydrocolloid, sodium alginate, chitosan, xanthan gum, guar gum, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, or a combination thereof. In some embodiments, the bio-adhesive agent does not cause irritation to the skin. In some embodiments, the inner layer comprises a matrix of fibers. In some embodiments, the matrix of fibers comprises cotton, water-absorbing hydrogel, or porous- polymer coated pad. In some embodiments, the inner layer comprises a nonstick pad that is configured not to stick to the area affected by stye or chalazion. In some embodiments, thebandage is configured to be gently removed from the skin. In some embodiments, the bandage is sterilized.

[0014] In some embodiments, the bandage is configured to stay on for one day, two days, three days, or a desired period. In some embodiments, the bandage provides heat to the area affected by stye or chalazion.

[0015] In some embodiments, the palpebra comprises superior palpebra and inferior palpebra. In some embodiments, the bandage comprises an eye patch, an eye mask, an eye bandage, or an eye strip.

[0016] In certain aspects, this disclosure also provides a method for delivering one or more therapeutic agents to an area affected by stye or chalazion of a subject in need thereof comprising: a) providing the bandage disclosed herein to the subject; b) putting the bandage on the area affected by stye or chalazion of the subject; c) pressing gently to secure the bandage and to deliver the one or more therapeutic agents to the area affected by stye or chalazion; d) keeping the bandage on the affected area for a desired period; e) removing the bandage; and f) repeating from a) to e) if desired.

[0017] In some embodiments, the desired period is about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 15 hours, about 20 hours, about 24 hours, about 36 hours, or about 48 hours before it is removed.

[0018] In some aspects, this disclosure relates to a kit, comprising the bandage disclosed herein and an instruction for the usage of the bandage.

[0019] In some aspects, this disclosure also provides a method of treating stye or chalazion comprising applying a bandage on the stye or chalazion, wherein the bandage has a geometric shape to fit contour of an eyelid.

[0020] In some embodiments, the method further comprises, before applying the bandage on the stye or chalazion, applying a warm compress to the affected area. In some embodiments, the method further comprises, before applying the bandage on the stye or chalazion, washing and drying the affected area. In some embodiments, the method further comprises, slowly removing the bandage and replacing the bandage at a desired time period.

[0021] In some embodiments, the desired period ranges about 1 hour to 24 hours.

[0022] In some embodiments, the bandage comprises a hydrocolloid patch. In some embodiments, the bandage comprises an oval, crescent, circular, semi-circular, or geometric shape to fit contour of the eyelid and to fit over the area affected by stye or chalazion. In some embodiments, the bandage has a circular shape with a diameter of about 0.1 inches to about 0.6 inches. In some embodiments, the bandage is a 10 mm round patch. In some embodiments, thebandage is a 8 mm round patch. In some embodiments, the bandage has semi-circular shape with a radius of 0.205 inches. In some embodiments, the bandage is a 10 mm semi-circular patch.

[0023] In some embodiments, the bandage covers and protects skin over stye or chalazion. In some embodiments, the bandage is a clear patch. In some embodiments, the bandage has no parabens, fragrances, sulfates, or dyes. In some embodiments, the bandage is latex free.

[0024] In some embodiments, the bandage has a single layer. In some embodiments, the bandage has two or more layers.

[0025] In some embodiments, the bandage absorbs secretions. In some embodiments, the method decreases redness and swelling of the affected area. In some embodiments, the method reduces risk of scarring.

[0026] In some embodiments, the bandage is flexible and molded to the area affected by stye or chalazion. In some embodiments, the bandage is configured to blend into the skin or to be invisible. In some embodiments, color or texture of the bandage is configured to blend into the skin or to be invisible.

[0027] In some embodiments, the bandage carries one or more therapeutic agents. In some embodiments, the one or more therapeutic agents are disposed on the center of inner surface of the bandage. In some embodiments, the one or more therapeutic agents are disposed on the entire inner surface of the bandage. In some embodiments, the one or more therapeutic agents are selected from the group consisting of steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof. In some embodiments, the one or more therapeutic agents are selected so that they do not cause irritation to the eye or make the subject's vision blurry. In some embodiments, the one or more therapeutic agents are selected so that they increase blood circulation of the area affected by stye or chalazion. In some embodiments, the one or more therapeutic agents are selected so that they reduce pain or inflammation of the area affected by stye or chalazion.

[0028] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.INCORPORATION BY REFERENCE

[0029] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (“FIGURE.” or “FIGURES.” herein) of which:

[0031] FIG. 1 A illustrates a circular hydrocolloid dressing that is placed directly on top of a chalazion (which is usually located away from the upper or lower eyelid margin), in accordance with one or more embodiments of the present disclosure.

[0032] FIG. IB illustrates an oval (could be semi-circular) hydrocolloid dressing that is placed directly on top of a stye (which is usually located directly on the eyelid margin by the eyelash follicles), in accordance with one or more embodiments of the present disclosure.DETAILED DESCRIPTION

[0033] This disclosure pertains to versatile, compact hydrocolloid adhesive patches, approximately 1cm in size and available in a variety of shapes such as oval, round, semi-circular, or crescent. These patches are specifically designed for individuals suffering from eyelid conditions such as sties, hordeola, or chalazia, providing targeted and effective treatment.

[0034] Styes and chalazia are common eyelid conditions, affecting millions of individuals annually. These conditions arise from either a blockage in the meibomian glands in the eyelids or an infection of one of the follicles at the eyelid margin. Currently, the treatment protocol entails the application of warm compresses over the affected area, combined with topical antibiotic ointments like bacitracin or erythromycin, to lubricate the eyes, cleanse the eyelids of bacteria, and manage any irritation these conditions may cause.

[0035] However, given the dynamic and active nature of the eyelids, which constantly blink, these antibiotic ointments do not stay precisely where applied. Instead, they tend to run over the eyelid skin and enter the eye, thus diluting their effectiveness, necessitating frequent reapplications, and causing potential discomfort. The inadvertent introduction of ointment into the eye may also result in blurry vision and irritation.

[0036] This scenario highlights a pressing need for a product specifically designed to keep anti-inflammatory compositions precisely positioned on the eyelid, thereby maximizing their effectiveness, and minimizing discomfort and vision disruption. Adhesive bandages might seem to be a logical solution to this issue, but due to the eyelid's unique physical characteristics — small area, curved shape, and constant movement — conventional bandages do not adhere effectively or stay in place long enough to deliver therapeutic benefits.

[0037] To address this challenge, the present disclosure provides the use of a hydrocolloid adhesive material. Hydrocolloid patches can be crafted in various shapes, such as oval, crescent, circular or semi-circular, to fit the unique contours of the eyelid and be applied directly over a stye or a chalazion. The superior adhesive properties of these hydrocolloid patches allow them to remain securely in place for prolonged periods without falling off, even overnight. Beyond their adhesive capabilities, these patches can offer additional benefits. They can serve as a discreet dressing to camouflage eyelid swelling and inflammation, immediately improving the cosmetic appearance of the affected eye. The hydrocolloid patch may also prevent the user, especially children, from inadvertently picking at the affected area, promoting quicker healing.

[0038] Importantly, the undersurface of these hydrocolloid patches could be pretreated with various compositions known to decrease inflammation and unclog pores. These may include salicylic acid, niacinamide, or even benzoyl peroxide, which can be applied directly and focally on top of a stye or chalazion. Other compositions like methyl salicylate or menthol could potentially be used to heat the eyelid and promote faster healing.

[0039] For a chalazion that has already ruptured, a hydrocolloid patch would function as an ideal dressing to help absorb exudates and keep the area dry and clean, thereby reducing the risk of further infection. The hydrocolloid patches, when applied directly over styes or chalazia, represent a practical relief for the countless individuals who struggle with these conditions each year. By keeping the necessary therapeutic agents precisely where needed on the eyelid, these patches ensure effective treatment and faster recovery.BANDAGE

[0040] In certain aspects, the present disclosure provides a bandage configured to contour to an eye and append to skin of the palpebra of a subject. In some embodiments, the bandage comprises: (i) an inner layer, in contact with the skin of the palpebra, having a first surface that is adhesive to the skin of the palpebra and a second surface that is adhesive to an outer layer, wherein one or more therapeutic agents are disposed on or within the first surface of the inner layer; and (ii) the outer layer attached to the second surface of the inner layer and configured to resist permeation of water.

[0041] In some embodiments, a surface area of the bandage is about 5 mm2to about 200 mm2. In some embodiments, a surface area of the bandage is 2 mm2, 5 mm2, 6 mm2, 7 mm2, 8 mm2, 9 mm2, 10 mm2, 12 mm2, 14 mm2, 16 mm2, 18 mm2, 20 mm2, 25 mm2, 30 mm2, 35 mm2, 40 mm2, 45 mm2, 50 mm2, 55 mm2, 60 mm2, 65 mm2, 70 mm2, 75 mm2, 80 mm2, 85 mm2, 90 mm2, 95 mm2, 100 mm2, 110 mm2, 120 mm2, 130 mm2, 140 mm2, 150 mm2, 160 mm2, 170 mm2, 180 mm2, 190 mm2, or 200 mm2. In some embodiments, a surface area of the bandage is about 2 mm2, about 5 mm2, about 6 mm2, about 7 mm2, about 8 mm2, about 9 mm2, about 10 mm2, about 12 mm2, about 14 mm2, about 16 mm2, about 18 mm2, about 20 mm2, about 25 mm2, about 30 mm2, about 35 mm2, about 40 mm2, about 45 mm2, about 50 mm2, about 55 mm2, about 60 mm2, about 65 mm2, about 70 mm2, about 75 mm2, about 80 mm2, about 85 mm2, about 90 mm2, about 95 mm2, about 100 mm2, about 110 mm2, about 120 mm2, about 130 mm2, about 140 mm2, about 150 mm2, about 160 mm2, about 170 mm2, about 180 mm2, about 190 mm2, or about 200 mm2, including all values and sub ranges in between. In some embodiments, a surface area of the bandage is at least 2 mm2, at least 5 mm2, at least 6 mm2, at least 7 mm2, at least 8 mm2, at least 9 mm2, at least 10 mm2, at least 12 mm2, at least 14 mm2, at least 16 mm2, at least 18 mm2, at least 20 mm2, at least 25 mm2, at least 30 mm2, at least 35 mm2, at least 40 mm2, at least 45 mm2, at least 50 mm2, at least 55 mm2, at least 60 mm2, at least 65 mm2, at least 70 mm2, at least 75 mm2, at least 80 mm2, at least 85 mm2, at least 90 mm2, at least 95 mm2, at least 100 mm2, at least 110 mm2, at least 120 mm2, at least 130 mm2, at least 140 mm2, at least 150 mm2, at least 160 mm2, at least 170 mm2, at least 180 mm2, at least 190 mm2, or at least 200 mm2. In some embodiments, a surface area of the bandage is at most 2 mm2, at most 5 mm2, at most 6 mm2, at most 7 mm2, at most 8 mm2, at most 9 mm2, at most 10 mm2, at most 12 mm2, at most 14 mm2, at most 16 mm2, at most 18 mm2, at most 20 mm2, at most 25 mm2, at most 30 mm2, at most 35 mm2, at most 40 mm2, at most 45 mm2, at most 50 mm2, at most 55 mm2, at most 60 mm2, at most 65 mm2, at most 70 mm2, at most 75 mm2, at most 80 mm2, at most 85 mm2, at most 90 mm2, at most 95 mm2, at most 100 mm2, at most 110 mm2, at most 120 mm2, at most 130 mm2, at most 140 mm2, at most 150 mm2, at most 160 mm2, at most 170 mm2, at most 180 mm2, at most 190 mm2, or at most 200 mm2. In some embodiments, a surface area of the bandage is about 6 mm2 to about 12 mm2. In some embodiments, a surface area of the bandage is about 18 mm2 to about 40 mm2. In some embodiments, a surface area of the bandage is about 10 mm2 to about 200 mm2. In some embodiments, a surface area of the bandage is about 25 mm2 to about 150 mm2. In some embodiments, a surface area of the bandage is about 50 mm2 to about 100 mm2. In some embodiments, a surface area of the bandage is about 30 mm2 to about 200 mm2. In some embodiments, a surface area of thebandage is about 40 mm2 to about 80 mm2. In some embodiments, a surface area of the bandage is about 50 mm2 to about 70 mm2.

[0042] In some embodiments, the outer layer is configured to blend into the skin or to be invisible.

[0043] In some embodiments, the bandage may have a circular, semi-circular, crescentshaped (crescentic), or geometric shape to fit over the area affected by stye or chalazion. In some embodiments, a shape of the bandage is configured to contour to an eye and append to skin of the palpebra of a subject. In some embodiments, a shape of the bandage is configured to contour to an eyelid.

[0044] In some embodiments, the inner layer may have a circular, semi-circular, crescentshaped (crescentic), or geometric shape to fit over the area affected by stye or chalazion. In some embodiments, the inner layer is circular and has a diameter of about 5 mm to about 20 mm. In some embodiments, the inner layer is circular and has a diameter of 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the inner layer is circular and has a diameter of about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 11 mm, about 12 mm, about 13 mm, about 14 mm, about 15 mm, about 16 mm, about 17 mm, about 18 mm, about 19 mm, or about 20 mm, including all values and sub ranges in between. In some embodiments, the inner layer is circular and has a diameter of at least 5 mm, at least 6 mm, at least 7 mm, at least 8 mm, at least 9 mm, at least 10 mm, at least 11 mm, at least 12 mm, at least 13 mm, at least 14 mm, at least 15 mm, at least 16 mm, at least 17 mm, at least 18 mm, at least 19 mm, or at least 20 mm. In some embodiments, the inner layer is circular and has a diameter of at most 5 mm, at most 6 mm, at most 7 mm, at most 8 mm, at most 9 mm, at most 10 mm, at most 11 mm, at most 12 mm, at most 13 mm, at most 14 mm, at most 15 mm, at most 16 mm, at most 17 mm, at most 18 mm, at most 19 mm, or at most 20 mm. In some embodiments, the inner layer is circular and has a diameter of 5 mm to 20 mm, 6 mm to 18 mm, 8 mm to 12 mm, or 10 mm to 16 mm.

[0045] In some embodiments, the inner layer may be flexible and molded to the area affected by stye or chalazion. In some embodiments, the outer layer may be flexible and contour to the eye. In some embodiments, the bandage comprises one layer combining the inner layer and the outer layer. In some embodiments, the bandage further comprises one or more additional layers.

[0046] In some embodiments, the bandage may cover part- or the entire upper or lower eyelid. In some embodiments, the bandage may cover a part of upper eyelid. In some embodiments, the bandage may cover a part of lower eyelid. In some embodiments, the bandage may cover the entire upper eyelid. In some embodiments, the bandage may cover the entirelower eyelid. In some embodiments, no portion of the bandage extends to the eye. The bandage may not interfere opening or closing of the eyelids. The bandage may remain on the eyelids, which constantly blink, for a desired period.

[0047] In some embodiments, the bandage may be configured to cover the skin of the palpebra without interfering with the subject’s vision or function of an eyelid. In some embodiments, the bandage may be configured to cover an area affected by stye or chalazion without interfering with the subject’s vision or function of an eyelid.

[0048] In some embodiments, the inner layer may be centrally adhesively attached to the outer layer. In some embodiments, the outer layer extends over and covers the inner layer. In some embodiments, the outer layer may be the same size as the inner layer. In some embodiments, the outer layer has a third surface that may be adhesive to the second surface of the inner layer and a fourth surface that faces opposite to the skin. In some embodiments, the third surface of the outer layer may be configured to be adhesive to skin around the palpebra without interfering with the subject’s vision or function of an eyelid.

[0049] In some embodiments, the exterior surface of the bandage has one or more of the following characteristics: a variety of colors available to match skin tone, a neutral color in which makeup can be applied on top of the bandage, and a matte surface.

[0050] In some embodiments, a bio-adhesive agent is disposed on a peripheral area of the third surface of the outer layer. In some embodiments, a bio-adhesive agent may be disposed on the first surface of the inner layer. In some embodiments, the bio-adhesive agent may be selected from the group consisting of methacrylate, epoxy diacrylate (vinyl resin), hydrocolloid, sodium alginate, chitosan, xanthan gum, guar gum, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, or a combination thereof. In some embodiments, the bio-adhesive agent does not cause irritation to the skin.

[0051] In some embodiments, a bio-adhesive agent is disposed on a peripheral area of the third surface of the outer layer. In some embodiments, for the third surface of the outer layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bioadhesive agent is 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100%. In some embodiments, for the third surface of the outer layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bio-adhesive agent is about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 100%, including all values and sub ranges in between. In some embodiments, for the third surface of the outer layer, the surface area ratio between the surface with bio-adhesiveagent and the surface without bio-adhesive agent is at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 100%. In some embodiments, for the third surface of the outer layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bio-adhesive agent is at most 2%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, at most 95%, at most 98%, or at most 100%.

[0052] In some embodiments, a bio-adhesive agent may be disposed on the first surface of the inner layer. In some embodiments, for the first surface of the inner layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bio-adhesive agent is 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100%. In some embodiments, for the first surface of the inner layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bioadhesive agent is about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 100%, including all values and sub ranges in between. In some embodiments, for the first surface of the inner layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bio-adhesive agent is at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 100%. In some embodiments, for the first surface of the inner layer, the surface area ratio between the surface with bio-adhesive agent and the surface without bio-adhesive agent is at most 2%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, at most 95%, at most 98%, or at most 100%.

[0053] In some embodiments, the inner layer comprises a matrix of fibers. In some embodiments, the matrix of fibers comprises cotton, water-absorbing hydrogel, or porous- polymer coated pad. In some embodiments, the inner layer comprises a nonstick pad that is configured not to stick to the area affected by stye or chalazion.

[0054] In some embodiments, the bandage comprises hydrocolloid patches. In some embodiments, the inner layer comprises a hydrocolloid patch. In some embodiments, the innerlayer and outer layer combine to make one layer comprising a hydrocolloid patch. In some embodiments, the bandage comprises one layer comprising a hydrocolloid patch. The hydrocolloid patches can be crafted in various shapes, such as oval, crescent, circular or semicircular, to fit the unique contours of the eyelid and be applied directly over a stye or a chalazion. The hydrocolloid patches may remain securely in place for prolonged periods without falling off, even overnight. The hydrocolloid patches may serve as a discreet dressing to camouflage eyelid swelling and inflammation, immediately improving the cosmetic appearance of the affected eye. The hydrocolloid patch may prevent the user, especially children, from inadvertently picking at the affected area, promoting quicker healing. In some embodiments, the undersurface of the hydrocolloid patches could be pretreated with various compositions known to decrease inflammation and unclog pores.

[0055] In some embodiments, the hydrocolloid patch may have a circular, semi-circular, crescent-shaped (crescentic), or geometric shape to fit contour of the eyelid and to fit over the area affected by stye or chalazion. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of about 5 mm to about 20 mm. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 11 mm, about 12 mm, about 13 mm, about 14 mm, about 15 mm, about 16 mm, about 17 mm, about 18 mm, about 19 mm, or about 20 mm, including all values and sub ranges in between. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of at least 5 mm, at least 6 mm, at least 7 mm, at least 8 mm, at least 9 mm, at least 10 mm, at least 11 mm, at least 12 mm, at least 13 mm, at least 14 mm, at least 15 mm, at least 16 mm, at least 17 mm, at least 18 mm, at least 19 mm, or at least 20 mm. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of at most 5 mm, at most 6 mm, at most 7 mm, at most 8 mm, at most 9 mm, at most 10 mm, at most 11 mm, at most 12 mm, at most 13 mm, at most 14 mm, at most 15 mm, at most 16 mm, at most 17 mm, at most 18 mm, at most 19 mm, or at most 20 mm. In some embodiments, the inner layer is circular and has a diameter of 5 mm to 20 mm, 6 mm to 18 mm, 8 mm to 12 mm, or 10 mm to 16 mm.

[0056] In some embodiments, the hydrocolloid patch may have a circular, semi-circular, crescent-shaped (crescentic), or geometric shape to fit over the area affected by stye or chalazion. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of about 0.1 inches to about 0.6 inches. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of 0.1 inches, 0.15 inches, 0.2 inches, 0.22 inches, 0.24inches, 0.26 inches, 0.28 inches, 0.3 inches, 0.32 inches, 0.34 inches, 0.35 inches, 0.36 inches, 0.38 inches, 0.4 inches, 0.42 inches, 0.44 inches, 0.46 inches, 0.48 inches, 0.5 inches, 0.55 inches, or 0.6 inches. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of about 0.1 inches, about 0.15 inches, about 0.2 inches, about 0.22 inches, about 0.24 inches, about 0.26 inches, about 0.28 inches, about 0.3 inches, about 0.32 inches, about 0.34 inches, about 0.35 inches, about 0.36 inches, about 0.38 inches, about 0.4 inches, about 0.42 inches, about 0.44 inches, about 0.46 inches, about 0.48 inches, about 0.5 inches, about 0.55 inches, or about 0.6 inches, including all values and sub ranges in between. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of at least 0.1 inches, at least 0.15 inches, at least 0.2 inches, at least 0.22 inches, at least 0.24 inches, at least 0.26 inches, at least 0.28 inches, at least 0.3 inches, at least 0.32 inches, at least 0.34 inches, at least 0.35 inches, at least 0.36 inches, at least 0.38 inches, at least 0.4 inches, at least 0.42 inches, at least 0.44 inches, at least 0.46 inches, at least 0.48 inches, at least 0.5 inches, at least 0.55 inches, or at least 0.6 inches. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of at most 0.1 inches, at most 0.15 inches, at most 0.2 inches, at most 0.22 inches, at most 0.24 inches, at most 0.26 inches, at most 0.28 inches, at most 0.3 inches, at most 0.32 inches, at most 0.34 inches, at most 0.35 inches, at most 0.36 inches, at most 0.38 inches, at most 0.4 inches, at most 0.42 inches, at most 0.44 inches, at most 0.46 inches, at most 0.48 inches, at most 0.5 inches, at most 0.55 inches, or at most 0.6 inches. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of 0.354 inches. In some embodiments, the hydrocolloid patch may be circular and may have a diameter of 0.314 inches.

[0057] In some embodiments, the hydrocolloid patch may be semi-circular and may have a width of about 0.1 inches to about 0.6 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a length (one radius) of 0.1 inches, 0.15 inches, 0.2 inches, 0.22 inches, 0.24 inches, 0.26 inches, 0.28 inches, 0.3 inches, 0.32 inches, 0.34 inches, 0.35 inches, 0.36 inches, 0.38 inches, 0.4 inches, 0.42 inches, 0.44 inches, 0.46 inches, 0.48 inches, 0.5 inches, 0.55 inches, or 0.6 inches. In some embodiments, the hydrocolloid patch may be semicircular and may have a length (one radius) of about 0.1 inches, about 0.15 inches, about 0.2 inches, about 0.22 inches, about 0.24 inches, about 0.26 inches, about 0.28 inches, about 0.3 inches, about 0.32 inches, about 0.34 inches, about 0.35 inches, about 0.36 inches, about 0.38 inches, about 0.4 inches, about 0.42 inches, about 0.44 inches, about 0.46 inches, about 0.48 inches, about 0.5 inches, about 0.55 inches, or about 0.6 inches, including all values and sub ranges in between. In some embodiments, the hydrocolloid patch may be semi-circular and may have a length (one radius) of at least 0.1 inches, at least 0.15 inches, at least 0.2 inches, at least 0.22 inches, at least 0.24 inches, at least 0.26 inches, at least 0.28 inches, at least 0.3 inches, atleast 0.32 inches, at least 0.34 inches, at least 0.35 inches, at least 0.36 inches, at least 0.38 inches, at least 0.4 inches, at least 0.42 inches, at least 0.44 inches, at least 0.46 inches, at least 0.48 inches, at least 0.5 inches, at least 0.55 inches, or at least 0.6 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a length (one radius) of at most 0.1 inches, at most 0.15 inches, at most 0.2 inches, at most 0.22 inches, at most 0.24 inches, at most 0.26 inches, at most 0.28 inches, at most 0.3 inches, at most 0.32 inches, at most 0.34 inches, at most 0.35 inches, at most 0.36 inches, at most 0.38 inches, at most 0.4 inches, at most 0.42 inches, at most 0.44 inches, at most 0.46 inches, at most 0.48 inches, at most 0.5 inches, at most 0.55 inches, or at most 0.6 inches. In some embodiments, the hydrocolloid patch may be semicircular and may have a width of 0.205 inches.

[0058] In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of about 0.1 inches to about 0.6 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of 0.1 inches, 0.15 inches, 0.2 inches, 0.22 inches, 0.24 inches, 0.26 inches, 0.28 inches, 0.3 inches, 0.32 inches, 0.34 inches, 0.35 inches, 0.36 inches, 0.38 inches, 0.4 inches, 0.42 inches, 0.44 inches, 0.46 inches, 0.48 inches, 0.5 inches, 0.55 inches, or 0.6 inches. In some embodiments, the hydrocolloid patch may be semicircular and may have a diameter of about 0.1 inches, about 0.15 inches, about 0.2 inches, about 0.22 inches, about 0.24 inches, about 0.26 inches, about 0.28 inches, about 0.3 inches, about 0.32 inches, about 0.34 inches, about 0.35 inches, about 0.36 inches, about 0.38 inches, about 0.4 inches, about 0.42 inches, about 0.44 inches, about 0.46 inches, about 0.48 inches, about 0.5 inches, about 0.55 inches, or about 0.6 inches, including all values and sub ranges in between. In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of at least 0.1 inches, at least 0.15 inches, at least 0.2 inches, at least 0.22 inches, at least 0.24 inches, at least 0.26 inches, at least 0.28 inches, at least 0.3 inches, at least 0.32 inches, at least 0.34 inches, at least 0.35 inches, at least 0.36 inches, at least 0.38 inches, at least 0.4 inches, at least 0.42 inches, at least 0.44 inches, at least 0.46 inches, at least 0.48 inches, at least 0.5 inches, at least 0.55 inches, or at least 0.6 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of at most 0.1 inches, at most 0.15 inches, at most 0.2 inches, at most 0.22 inches, at most 0.24 inches, at most 0.26 inches, at most 0.28 inches, at most 0.3 inches, at most 0.32 inches, at most 0.34 inches, at most 0.35 inches, at most 0.36 inches, at most 0.38 inches, at most 0.4 inches, at most 0.42 inches, at most 0.44 inches, at most 0.46 inches, at most 0.48 inches, at most 0.5 inches, at most 0.55 inches, or at most 0.6 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of 0.354 inches. In some embodiments, the hydrocolloid patch may be semi-circular and may have a diameter of 0.354 inches and another radius of 0.205 inches.

[0059] The bandage is capable of holding and delivering one or more therapeutic agents. In some embodiments, the one or more therapeutic agents may be applied to the inner surface of the bandage in contact with the eyelid skin for treating stye and / or chalazion.

[0060] In some embodiments, the bandage may be configured to be gently removed from the skin.

[0061] In some embodiments, the bandage is sterilized.

[0062] In some embodiments, the bandage may be configured to stay on for one day, two days, three days, or a desired period.

[0063] In some embodiments, the bandage provides heat to the area affected by stye or chalazion.

[0064] In some embodiments, the palpebra comprises superior palpebra and inferior palpebra.

[0065] In some embodiments, the bandage comprises an eye patch, an eye mask, an eye bandage, or an eye strip.

[0066] In some embodiments, the bandage may absorb secretions. In some embodiments, the bandage may help decrease redness. In some embodiments, the bandage may help decrease swelling. In some embodiments, the bandage may reduce risk of scarring.

[0067] In some embodiments, the bandage may be for a single use.

[0068] In some embodiments, the bandage may be clear.

[0069] In some embodiments, the bandage may be an 8 mm round patch. In some embodiments, the bandage may be an 8 mm semi-circular patch.

[0070] In some embodiments, the bandage may not comprise parabens, fragrances, sulfates, or dyes. In some embodiments, the bandage may be latex free.THERAPEUTIC AGENT

[0071] In some embodiments, the one or more therapeutic agents may be effective for treating stye, hordeola, and / or chalazion. In some embodiments, the one or more therapeutic agents may be effective for treating stye. In some embodiments, the one or more therapeutic agents may be effective for treating hordeola. In some embodiments, the one or more therapeutic agents may be effective for treating chalazion.

[0072] In some embodiments, the one or more therapeutic agents may increase blood circulation of the area affected by stye, hordeola, or chalazion. In some embodiments, the one or more therapeutic agents may increase blood circulation of the area affected by stye. In some embodiments, the one or more therapeutic agents may increase blood circulation of the areaaffected by hordeola. In some embodiments, the one or more therapeutic agents may increase blood circulation of the area affected by chalazion.

[0073] In some embodiments, the one or more therapeutic agents may reduce pain of the area affected by stye, hordeola, or chalazion. In some embodiments, the one or more therapeutic agents may reduce pain of the area affected by stye. In some embodiments, the one or more therapeutic agents may reduce pain of the area affected by hordeola. In some embodiments, the one or more therapeutic agents may reduce pain of the area affected by chalazion.

[0074] In some embodiments, the one or more therapeutic agents may reduce inflammation of the area affected by stye, hordeola, or chalazion. In some embodiments, the one or more therapeutic agents may reduce inflammation of the area affected by stye. In some embodiments, the one or more therapeutic agents may reduce inflammation of the area affected by hordeola. In some embodiments, the one or more therapeutic agents may reduce inflammation of the area affected by chalazion.

[0075] In some embodiments, the one or more therapeutic agents may unclog pores by stye, hordeola, or chalazion. In some embodiments, the one or more therapeutic agents may unclog pores by stye. In some embodiments, the one or more therapeutic agents may unclog pores by hordeola. In some embodiments, the one or more therapeutic agents may unclog pores by chalazion.

[0076] In some embodiments, the one or more therapeutic agents may absorb secretions. In some embodiments, the one or more therapeutic agents may help decrease redness. In some embodiments, the one or more therapeutic agents may help decrease swelling. In some embodiments, the one or more therapeutic agents may reduce risk of scarring.

[0077] In some embodiments, the one or more therapeutic agents includes, but are not limited to steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof. In some embodiments, the one or more therapeutic agents are selected from steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof. In some embodiments, the one or more therapeutic agents comprise salicylic acid, niacinamide, or benzoyl peroxide. In some embodiments, the one or more therapeutic agents comprise salicylic acid or niacinamide. In some embodiments, the one or more therapeutic agents comprise salicylic acid, niacinamide, or benzoyl peroxide, which can be applied directly and focally on top of a stye or chalazion. Other compositions like methyl salicylate or menthol could potentially be used to heat the eyelid and promote faster healing.

[0078] In some embodiments, the one or more therapeutic agents comprises salicylic acid niacinamide, or combinations thereof. In some embodiments, the one or more therapeutic agents comprises salicylic acid and niacinamide. In some embodiments, the one or more therapeutic agents comprises salicylic acid. In some embodiments, the one or more therapeutic agents comprises niacinamide.

[0079] The one or more therapeutic agents may not cause irritation to the eye or make the subject's vision blurry. In some embodiments, the one or more therapeutic agents are selected so that they do not cause irritation to the eye or make the subject's vision blurry. In some embodiments, the one or more therapeutic agents naturally do not cause irritation to the eye or make the subject's vision blurry. In some embodiments, an amount of the one or more therapeutic agents, which is provided by the bandage, do not cause irritation to the eye or make the subject's vision blurry. In some embodiments, the one or more therapeutic agents remain near the eye to avoid irritation to the eye or make the subject's vision blurry.

[0080] In some embodiments, the one or more therapeutic agents may be disposed on the undersurface of the hydrocolloid patches, which may be in contact with the skin of the palpebra. In some embodiments, the one or more therapeutic agents may be disposed on the undersurface of the hydrocolloid patches, which may be in contact with the skin of the eyelids. In some embodiments, the one or more therapeutic agents may be disposed on the first surface of the inner layer with bio-adhesive agents. In some embodiments, the one or more therapeutic agents may be disposed on the first surface of the inner layer with no bio-adhesive agents.METHOD

[0081] In certain aspects, this disclosure provides a method for delivering one or more therapeutic agents to an area affected by stye, hordeola, or chalazion of a subject in need thereof. The method comprises a) providing the bandage disclosed herein to the subject; b) putting the bandage on the area affected by stye or chalazion of the subject; c) pressing the bandage gently to secure it and to deliver the one or more therapeutic agents to the area affected by stye or chalazion; d) keeping the bandage on the affected area for a desired period; e) removing the bandage; and f) repeating from a) to e) if desired.

[0082] In some embodiments, the method comprises (i) applying a warm compress to the affected area, (ii) washing and drying the affected area, (iii) applying a bandage disclosed herein on the stye or chalazion, and (iv) slowly removing the bandage and replacing at a desired time period. In some embodiments, the bandage may be replaced every 1 hour. In some embodiments, the bandage may be replaced every 2 hours. In some embodiments, the bandage may be replaced every 3 hours. In some embodiments, the bandage may be replaced every 4 hours. In someembodiments, the bandage may be replaced every 5 hours. In some embodiments, the bandage may be replaced every 6 hours. In some embodiments, the bandage may be replaced every 8 hours. In some embodiments, the bandage may be replaced every 12 hours. In some embodiments, the bandage may be replaced every 16 hours. In some embodiments, the bandage may leave overnight.

[0083] In some embodiments, the bandage may be applied to the affected area, deliver the one or more therapeutic agents, and be left on the skin for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 24 hours, 36 hours, or 48 hours before it is removed. In some embodiments, the bandage may be applied to the affected area, deliver the one or more therapeutic agents, and be left on the skin for at least 1 hour, least 2 hours, least 3 hours, least 4 hours, least 5 hours, least 6 hours, least 7 hours, least 8 hours, least 9 hours, least 10 hours, least 11 hours, least 12 hours, least 13 hours, least 14 hours, least 15 hours, least 16 hours, least 17 hours, least 18 hours, least 19 hours, at least 20 hours, at least 24 hours, at least 36 hours, or at least 48 hours before it is removed. In some embodiments, the bandage may be applied to the affected area, deliver the one or more therapeutic agents, and be left on the skin for at most 1 hour, at most 2 hours, at most 3 hours, at most 4 hours, at most 5 hours, at most 6 hours, at most 7 hours, at most 8 hours, at most 9 hours, at most 10 hours, at most 11 hours, at most 12 hours, at most 13 hours, at most 14 hours, at most 15 hours, at most 16 hours, at most 17 hours, at most 18 hours, at most 19 hours, at most 20 hours, at most 24 hours, at most 36 hours, or at most 48 hours before it is removed. In some embodiments, the bandage may be applied to the affected area, deliver the one or more therapeutic agents, and be left on the skin for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 24 hours, about 36 hours, or about 48 hours before it is removed.KIT

[0084] This disclosure also relates to a kit for treating stye, hordeola, and / or chalazion. In some embodiments, the kit comprises the bandage disclosed herein and an instruction.DEFINITIONS

[0085] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. Insome cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0086] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0087] As used in the specification and claims, the singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.

[0088] Whenever the term “at least,” “greater than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “at least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0089] Whenever the term “no more than,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0090] The term “exemplary” as used herein means “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not to be construed as preferred or advantageous over other embodiments.

[0091] The terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” are often used interchangeably herein to refer to forms of measurement. The terms include determining if an element is present or not (for example, detection). These terms can include quantitative, qualitative, or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of’ can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.

[0092] The terms “subject,” “individual,” or “patient” are often used interchangeably herein. A “subject” can be a biological entity containing expressed genetic materials. The biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject can be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro. The subject can be a mammal. The mammal can be a human. The subject may be diagnosed or suspected of being at high risk for a disease. In some cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease.

[0093] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.

[0094] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying, or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.

[0095] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.LIST OF EMBODIMENTS

[0096] The following list of embodiments of the invention are to be considered as disclosing various features of the invention, which features can be considered to be specific to the particular embodiment under which they are discussed, or which are combinable with the various other features as listed in other embodiments. Thus, simply because a feature is discussed under one particular embodiment does not necessarily limit the use of that feature to that embodiment.

[0097] Embodiment 1. A small bandage (can be circular or semi-circular around 8-10mm in size) configured to contour to the upper / lower eyelid and append to the skin of the palpebra of a subject over a Stye or a Chalazion.

[0098] Embodiment 2. The bandage of embodiment 1, wherein the bandage has an area of about 6 mm2 to about 12 mm2.

[0099] Embodiment 3. The bandage of embodiment 1, wherein the bandage is circular, semicircular, oval, or crescent shaped.

[0100] Embodiment 4. The bandage of embodiment 1, wherein the bandage may cover part- or the entire upper or lower eyelid.

[0101] Embodiment 5. The bandage of embodiment 1, wherein the bandage has a surface area of about 18 mm2 to about 40 mm2.

[0102] Embodiment 6. The bandage of any one of embodiments 1 to 5, wherein one or more therapeutic agents is applied to the inner surface of the bandage in contact with the eyelid skin for treating stye and / or chalazion.

[0103] Embodiment 7. The bandage of any one of embodiments 1 to 6, wherein the bandage is configured to cover the skin of the palpebra without interfering with the subject’s ability to blink or obstruct vision.

[0104] Embodiment 8. The bandage of any one of embodiments 1 to 8, wherein the bandage is configured to cover an area affected by a stye or chalazion without interfering with the subject’s vision or function of an eyelid.

[0105] Embodiment 9. The bandage of any one of embodiments 1 to 8, wherein the inner layer is centrally adhesively attached to the outer layer.

[0106] Embodiment 10. The bandage of any one of embodiments 1 to 8, wherein the outer layer extends over and covers the inner layer.

[0107] Embodiment 11. The bandage of any one of embodiments 1 to 8, wherein the outer layer is the same size as the inner layer.

[0108] Embodiment 12. The bandage of any one of embodiments 1 to 8, wherein the outer layer is configured to blend into the skin or to be invisible.

[0109] Embodiment 13. The bandage of any one of embodiments 1 to 8, wherein the inner layer has a circular, semi-circular, or any geometric shape to fit over the area affected by stye or chalazion.

[0110] Embodiment 14. The bandage of any one of embodiments 1 to 8, wherein the inner layer is circular and has a diameter of about 5 mm to about 15 mm.[OHl] Embodiment 15. The bandage of any one of embodiments 1 to 8, wherein the outer layer is flexible and contour to the eye.

[0112] Embodiment 16. The bandage of any one of embodiments 1 to 8, wherein the bandage comprises one layer combining the inner layer and the outer layer.

[0113] Embodiment 17. The bandage of any one of embodiments 1 to 8, further comprising one or more additional layers.

[0114] Embodiment 18. The bandage of any one of embodiments 1 to 8, wherein the one or more therapeutic agents increase blood circulation of the area affected by stye or chalazion.

[0115] Embodiment 19. The bandage of any one of embodiments 1 to 8, wherein the one or more therapeutic agents reduce pain or inflammation of the area affected by stye or chalazion.

[0116] Embodiment 20. The bandage of any one of embodiments 1 to 19, wherein the one or more therapeutic agents are selected from the group consisting of steroids, non-steroidal antiinflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof.

[0117] Embodiment 21. The bandage of embodiment 20, wherein the one or more therapeutic agents comprises salicylic acid, niacinamide, or combinations thereof.

[0118] Embodiment 22. The bandage of any one of embodiments 1 to 19, wherein the one or more therapeutic agents do not cause irritation to the eye or make the subject's vision blurry.

[0119] Embodiment 23. The bandage of any one of embodiments 1 to 19, wherein the bioadhesive agent is selected from the group consisting of methacrylate, epoxy diacrylate (vinyl resin), hydrocolloid, sodium alginate, chitosan, xanthan gum, guar gum, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, or a combination thereof.

[0120] Embodiment 24. The bandage of any one of embodiments 1 to 23, wherein the bioadhesive agent does not cause irritation to the skin.

[0121] Embodiment 25. The bandage of any one of embodiments 1 to 23, wherein the inner layer comprises a matrix of fibers.

[0122] Embodiment 26. The bandage of any one of embodiments 1 to 23, wherein the matrix of fibers comprises cotton, water-absorbing hydrogel, or porous-polymer coated pad.

[0123] Embodiment 27. The bandage of any one of embodiments 1 to 23, wherein the inner layer comprises a nonstick pad that is configured not to stick to the area affected by stye or chalazion.

[0124] Embodiment 28. The bandage of any one of embodiments 1 to 23, wherein the bandage is configured to be gently removed from the skin.

[0125] Embodiment 29. The bandage of any one of embodiments 1 to 23, wherein the bandage is sterilized.

[0126] Embodiment 30. The bandage of any one of embodiments 1 to 23, wherein the bandage provides heat to the area affected by stye or chalazion (e.g., Menthol or Methyl Salicylate).

[0127] Embodiment 31. The bandage of any one of embodiments 1 to 23, wherein the palpebra comprises superior palpebra and inferior palpebra.

[0128] Embodiment 32. The bandage of any one of embodiments 1 to 23, wherein the bandage comprises an eye patch, an eye mask, an eye bandage, or an eye strip.

[0129] Embodiment 33. A method for delivering one or more therapeutic agents to an area affected by stye or chalazion of a subject in need thereof: a) providing the bandage of embodiments 1 to 32; b) putting the bandage on the area affected by stye or chalazion; c) pressing gently to secure the bandage and to deliver the one or more therapeutic agents to the area affected by stye or chalazion; d) keeping the bandage on the affected area for a desired period; e) removing the bandage; and f) repeating from a) to e).

[0130] Embodiment 34. The method of embodiment 33, wherein the desired period is at least 2 hours, at least 4 hours, at least 6 hours, at least 8, at least 10, at least 15 hours, at least 20 hours, at least 24 hours, at least 36 hours, or at least 48 hours before it is removed.

[0131] Embodiment 35. A kit, comprising the bandage of embodiments 1 to 32 and an instruction.EXAMPLES

[0132] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.Example 1: Treatment of sties by the eye bandage

[0133] A human subject suffering from severe symptoms of sties is treated with an eye bandage that comprises one or more therapeutic agents comprising salicylic acid, niacinamide, or benzoyl peroxide. The one or more therapeutic agents are administered directly and focally on top of the affected area of the human subject by applying the eye bandage disclosed herein. The eye bandage that comprises one or more therapeutic agents helps decrease inflammation, unclogs skin pores, and even promotes better circulation to the area to help expedite the healing of such conditions. The eye bandage comprises a hydrocolloid adhesive material with excellent adhesive properties, thus it is maintained in contact with the skin of the subject for hours without falling off (even overnight). The bandage also helps protect the inflamed eyelid skin, absorbexudates / debris, and prevent the user from picking at it. At the end of the treatment, the subject is free of symptoms associated with sties.

[0134] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

CLAIMS1. A bandage configured to contour to an eye and append to skin of the palpebra of a subject, wherein the bandage comprises: an inner layer, in contact with the skin of the palpebra, having a first surface that is adhesive to the skin of the palpebra and a second surface that is adhesive to an outer layer, wherein one or more therapeutic agents are disposed on or within the first surface of the inner layer; and the outer layer attached to the second surface of the inner layer and configured to resist permeation of water.

2. The bandage of claim 1, wherein a surface area of the bandage is about 30 mm2to about 200 mm2.

3. The bandage of claim 1, wherein a surface area of the bandage is about 40 mm2to about 80 mm2.

4. The bandage of claim 1, wherein a surface area of the bandage is about 50 mm2to about 70 mm2.

5. The bandage of any one of claims 1 to 4, wherein the one or more therapeutic agents is effective for treating stye and / or chalazion.

6. The bandage of any one of claims 1 to 5, wherein the bandage is configured to cover the skin of the palpebra without interfering with the subject’s vision or function of an eyelid.

7. The bandage of any one of claims 1 to 6, wherein the bandage is configured to cover an area affected by stye or chalazion without interfering with the subject’s vision or function of an eyelid.

8. The bandage of any one of claims 1 to 7, wherein the inner layer is centrally adhesively attached to the outer layer.

9. The bandage of any one of claims 1 to 8, wherein the outer layer extends over and covers the inner layer.

10. The bandage of any one of claims 1 to 9, wherein the outer layer is the same size as the inner layer.

11. The bandage of any one of claims 1 to 10, wherein the outer layer has a third surface that is adhesive to the second surface of the inner layer and a fourth surface that faces opposite to the skin.

12. The bandage of any one of claims 1 to 11, wherein the third surface of the outer layer is configured to be adhesive to skin around the palpebra without interfering with the subject’s vision or function of an eyelid.

13. The bandage of any one of claims 1 to 12, wherein a bio-adhesive agent is disposed on a peripheral area of the third surface of the outer layer.

14. The bandage of any one of claims 1 to 13, wherein a bio-adhesive agent is disposed on the first surface of the inner layer.

15. The bandage of any one of claims 1 to 14, wherein the outer layer is configured to blend into the skin or to be invisible.

16. The bandage of any one of claims 1 to 15, wherein the inner layer has a circular, semicircular, or a geometric shape to fit over the area affected by stye or chalazion.

17. The bandage of any one of claims 1 to 16, wherein the inner layer is circular and has a diameter of about 5 mm to about 15 mm.

18. The bandage of any one of claims 1 to 17, wherein the inner layer is flexible and molded to the area affected by stye or chalazion.

19. The bandage of any one of claims 1 to 18, wherein the outer layer is flexible and contour to the eye.

20. The bandage of any one of claims 1 to 19, wherein the bandage comprises one layer combining the inner layer and the outer layer.

21. The bandage of any one of claims 1 to 20, further comprising one or more additional layers.

22. The bandage of any one of claims 1 to 21, wherein the bandage comprises a hydrocolloid patch.

23. The bandage of any one of claims 1 to 22, wherein the hydrocolloid patch comprises an oval, crescent, circular, semi-circular, or geometric shape to fit contour of the eyelid and to fit over the area affected by stye or chalazion.

24. The bandage of any one of claims 1 to 23, wherein the hydrocolloid patch has a circular shape with a diameter of about 0.1 inches to about 0.6 inches.

25. The bandage of any one of claims 1 to 23, wherein the hydrocolloid patch has semicircular shape with a radius of 0.205 inches.

26. The bandage of any one of claims 1 to 25, wherein the one or more therapeutic agents increase blood circulation of the area affected by stye or chalazion.

27. The bandage of any one of claims 1 to 26, wherein the one or more therapeutic agents reduce pain or inflammation of the area affected by stye or chalazion.

28. The bandage of any one of claims 1 to 27, wherein the one or more therapeutic agents are selected from the group consisting of steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof.

29. The bandage of any one of claims 1 to 28, wherein the one or more therapeutic agents do not cause irritation to the eye or make the subject's vision blurry.

30. The bandage of any one of claims 1 to 29, wherein the bio-adhesive agent is selected from the group consisting of methacrylate, epoxy diacrylate (vinyl resin), hydrocolloid, sodium alginate, chitosan, xanthan gum, guar gum, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, or a combination thereof.

31. The bandage of any one of claims 1 to 30, wherein the bio-adhesive agent does not cause irritation to the skin.

32. The bandage of any one of claims 1 to 31, wherein the inner layer comprises a matrix of fibers.

33. The bandage of any one of claims 1 to 32, wherein the matrix of fibers comprises cotton, water-absorbing hydrogel, or porous-polymer coated pad.

34. The bandage of any one of claims 1 to 33, wherein the inner layer comprises a nonstick pad that is configured not to stick to the area affected by stye or chalazion.

35. The bandage of any one of claims 1 to 34, wherein the bandage is configured to be gently removed from the skin.

36. The bandage of any one of claims 1 to 35, wherein the bandage is sterilized.

37. The bandage of any one of claims 1 to 36, wherein the bandage is configured to stay on for one day, two days, three days, or a desired period.

38. The bandage of any one of claims 1 to 37, wherein the bandage provides heat to the area affected by stye or chalazion.

39. The bandage of any one of claims 1 to 38, wherein the palpebra comprises superior palpebra and inferior palpebra.

40. The bandage of any one of claims 1 to 39, wherein the bandage comprises an eye patch, an eye mask, an eye bandage, or an eye strip.

41. A method for delivering one or more therapeutic agents to an area affected by stye or chalazion of a subject in need thereof comprising: a) providing the bandage of claims 1 to 40 to the subject; b) putting the bandage on the area affected by stye or chalazion of the subject; c) pressing gently to secure the bandage and to deliver the one or more therapeutic agents to the area affected by stye or chalazion; d) keeping the bandage on the affected area for a desired period; e) removing the bandage; and f) repeating from a) to e) if desired.

42. The method of claim 41, wherein the desired period is about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 15 hours, about 20 hours, about 24 hours, about 36 hours, or about 48 hours before it is removed.

43. A kit, comprising the bandage of claims 1 to 40 and an instruction.

44. A method of treating stye or chalazion comprising applying a bandage on the stye or chalazion, wherein the bandage has a geometric shape to fit a contour of an eyelid.

45. The method of claim 44, wherein the bandage comprises an oval, crescent, circular, semi-circular, or geometric shape to fit the contour of the eyelid and to fit over the area affected by stye or chalazion.

46. The method of claim 44 or 45, wherein the bandage has a surface area of about 30 mm2to about 200 mm2.

47. The method of any one of claims 44 to 46, wherein the bandage has a circular shape.

48. The method of claim 47, wherein a diameter of the circular shape is about 0.1 inches to about 0.6 inches.

49. The method of claim 47, wherein the bandage has a circular shape with a diameter of about 10 mm.

50. The method of claim 47, wherein the bandage has a circular shape with a diameter of about 8 mm.

51. The method of any one of claims 44 to 46, wherein the bandage has semi-circular shape.

52. The method of claim 51, wherein the bandage has a semi-circular shape with one radius of about 10 mm.

53. The method of any one of claims 44 to 52, further comprising, prior to applying the bandage on the stye or chalazion, applying a warm compress to the affected area.

54. The method of any one of claims 44 to 53, further comprising, prior to applying the bandage on the stye or chalazion, washing and drying the affected area.

55. The method of any one of claims 44 to 54, following applying the bandage on the stye or chalazion, further comprising removing the bandage and replacing the bandage at a desired time period.

56. The method of any one of claims 44 to 55, wherein the desired period ranges about 1 hour to 24 hours.

57. The method of any one of claims 44 to 56, wherein the bandage comprises a hydrocolloid patch.

58. The method of any one of claims 44 to 57, wherein the bandage covers and protects skin over the stye or the chalazion.

59. The method of any one of claims 44 to 58, wherein a portion of the bandage is transparent.

60. The method of any one of claims 44 to 59, wherein the bandage is transparent.

61. The method of any one of claims 44 to 60, wherein the bandage has no parabens, fragrances, sulfates, or dyes.

62. The method of any one of claims 44 to 61, wherein the bandage is latex free.

63. The method of any one of claims 44 to 62, wherein the bandage has a single layer.

64. The method of any one of claims 44 to 62, wherein the bandage has two or more layers.

65. The method of any one of claims 44 to 64, wherein the bandage absorbs secretions.

66. The method of any one of claims 44 to 65, wherein the method decreases redness and swelling of the affected area.

67. The method of any one of claims 44 to 66, wherein the method reduces risk of scarring.

68. The method of any one of claims 44 to 67, wherein the bandage is flexible and molded to the area affected by stye or chalazion.

69. The method of any one of claims 44 to 68, wherein the bandage comprises material that is configured to blend into the skin or to be invisible.

70. The method of any one of claims 44 to 69, wherein color or texture of the bandage is configured to blend into the skin or to be invisible.

71. The method of any one of claims 44 to 70, wherein the bandage carries one or more therapeutic agents.

72. The method of any one of claims 44 to 71, wherein the bandage comprises an inner surface, wherein the inner surface is in contact with the stye or the chalazion.

73. The method of any one of claims 44 to 72, wherein the one or more therapeutic agents are disposed on the center of inner surface of the bandage.

74. The method of any one of claims 44 to 73, wherein the one or more therapeutic agents are disposed on the entire inner surface of the bandage.

75. The method of any one of claims 44 to 74, wherein the one or more therapeutic agents are selected from the group consisting of steroids, non-steroidal anti-inflammatory agents, keratolytic agents, salicylates, capsaicin, menthol, camphor, topical analgesics, and homeopathic agents, or a combination thereof.

76. The method of any one of claims 44 to 75, wherein the one or more therapeutic agents are selected so that they do not cause irritation to the eye or make the subject's vision blurry.

77. The method of any one of claims 44 to 76, wherein the one or more therapeutic agents are selected so that they increase blood circulation of the area affected by stye or chalazion.

78. The method of any one of claims 44 to 77, wherein the one or more therapeutic agents are selected so that they reduce pain or inflammation of the area affected by stye or chalazion.

Images